Drug intelligence / Profile preview

OstriGrow

Development stage: Unknown
Lead developer: Ostrich Pharma USA
Modality: Antibody-Based Therapeutics
Administration: Topical

Overview

**OstriGrow** is a topically administered hair-regrowth product developed by Ostrich Pharma and marketed under the OstriGen name for androgenetic alopecia. It is a fixed combination of four ostrich egg-yolk immunoglobulin Y antibodies directed against dihydrotestosterone, steroid 5-alpha-reductase, *Staphylococcus aureus*, and *Cutibacterium acnes*. The product is intended to neutralize dihydrotestosterone and reduce its local formation in hair follicles while targeting skin bacteria implicated by the developer's supporting research; ethanol is used as the topical vehicle. ([ostrigen.com](https://www.ostrigen.com/whats-in-ostrigrow/))

Brand names: OstriGrow

Targets

SRD5A (Steroid 5-alpha-reductase)AR (Adrenergic receptors)

Beyond the preview

Go deeper on OstriGrow.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OstriGrow.

Explore the full profile